Selective Transduction of Protease-rich Tumors by Matrix-metalloproteinase-targeted Retroviral Vectors
Overview
Authors
Affiliations
We recently showed that retroviral vectors can be targeted through protease substrate interactions. Infectivity is blocked by a polypeptide fused to the viral envelope glycoprotein (SU) and is restored when a protease cleaves the connecting linker, releasing the inhibitory polypeptide from the viral surface. Protease specificity is achieved by engineering the sequence of the linker. Here, using two different matrix-metalloproteinase (MMP)-activatable vectors, we demonstrated highly efficient and selective transduction of MMP-rich target cells in a heterogeneous cell population. In vivo, the MMP-targeted vectors showed strong selectivity for MMP-rich tumor xenografts. Protease-activatable vectors offer new possibilities for in vivo targeting of gene delivery.
Tong J, Evans A, Ho M, Guenther C, Brun M, Judd J J Control Release. 2019; 307:292-301.
PMID: 31252037 PMC: 7428868. DOI: 10.1016/j.jconrel.2019.06.034.
Physical, chemical, and synthetic virology: Reprogramming viruses as controllable nanodevices.
Chen M, Butler S, Chen W, Suh J Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018; 11(3):e1545.
PMID: 30411529 PMC: 6461522. DOI: 10.1002/wnan.1545.
Pericellular proteolysis in cancer.
Sevenich L, Joyce J Genes Dev. 2014; 28(21):2331-47.
PMID: 25367033 PMC: 4215179. DOI: 10.1101/gad.250647.114.
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
Zamarin D, Palese P Future Microbiol. 2012; 7(3):347-67.
PMID: 22393889 PMC: 4241685. DOI: 10.2217/fmb.12.4.
Current advances in retroviral gene therapy.
Yi Y, Noh M, Lee K Curr Gene Ther. 2011; 11(3):218-28.
PMID: 21453283 PMC: 3182074. DOI: 10.2174/156652311795684740.